Navigation Links
Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
Date:11/3/2008

THOUSAND OAKS, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it will hold its Business Review Meeting on Friday, Nov. 7, 2008 at the Millennium Broadway Hotel, 145 West 44th Street, New York City, beginning at 8 a.m. Eastern Time. Participating in the meeting will be Kevin Sharer, chairman and CEO, Roger M. Perlmutter, M.D., Ph.D., executive vice president, Research and Development, George Morrow, executive vice president, Global Commercial Operations, Robert Bradway, executive vice president and CFO, and other members of Amgen's senior management team.

Live video of the meeting will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's Web site, http://www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay 72 hours after the event.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit http://www.amgen.com.

CONTACT: Amgen, Thousand Oaks

David Polk, 805-447-4613 (media)

Arvind Sood, 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
11. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Eli Lilly and ... 2 data evaluating galcanezumab for the prevention of migraine ... which will take place April 22-28, 2017, in ... present four abstracts at AAN, including safety and patient ... factors associated with a reduction in monthly migraine headache ...
(Date:4/20/2017)... Woburn, MA (PRWEB) , ... April 20, 2017 ... ... high brightness light sources for advanced technology applications, announced today that Chief Executive ... Board (NAAB). , SEMI is the global industry association connecting the ...
(Date:4/20/2017)... 2017 For today, Stock-Callers.com redirects investors, ... development and clinical research aimed at treating diseases and medical ... Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), ... can access our complimentary research reports on these stocks now ... http://stock-callers.com/registration ...
(Date:4/19/2017)... ... 19, 2017 , ... Nobilis Therapeutics Announces Completion of Landmark NBTX-001 ... Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, Inc. ... assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
Breaking Biology News(10 mins):